Skip to Main Content

Paper Details

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>.
J Clin Oncol
33
2023
Breast Cancer, CBC, ER, ER-negative breast cancer, Germline, PV, PVs, Women, breast cancer, contralateral, estrogen, germline pathogenic variants, invasive breast cancer, patient, tumor, women
Author NameAffiliation
Eric C PolleyUniversity of Chicago
Eric C PolleyUniversity of Chicago
James V LaceyBeckman Research Institute of City of Hope
James V LaceyBeckman Research Institute of City of Hope
Christopher A HaimanKeck School of Medicine, University of Southern California
Christopher A HaimanKeck School of Medicine, University of Southern California
Kathryn J RuddyMayo Clinic
Janet E OlsonMayo Clinic
Esther M JohnStanford University School of Medicine
Esther M JohnStanford Cancer Institute, Stanford University School of Medicine
Hoda Anton-CulverUniversity of California irvine
Hoda Anton-CulverUniversity of California irvine
David E GoldgarUniversity of Utah
David E GoldgarUniversity of Utah
Susan M DomchekPerelman School of Medicine at the University of Pennsylvania
Susan M DomchekBasser Center for BRCA, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Katherine L NathansonPerelman School of Medicine at the University of Pennsylvania
Katherine L NathansonBasser Center for BRCA, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Peter KraftHarvard University T.H. Chan School of Public Health
Peter KraftHarvard University T.H. Chan School of Public Health
Fergus J CouchMayo Clinic
Fergus J CouchMayo Clinic
  • 1 - 22

Datasets

Release 1.2